Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan

Yuh Shyan Tsai, Tzong Shin Tzai, Nan Hua Chow, Wen Horng Yang, Yat Ching Tong, Johnny S.N. Lin, Chien Chen Chang, Hong Lin Cheng, Yung Ming Lin

研究成果: Article

19 引文 (Scopus)

摘要

Objectives: To explore the clinical significance of p53 and HER-2/neu coexpression by immunohistochemistry in patients with invasive bladder cancer in Taiwan. Methods: Paraffin-embedded tumor blocks were obtained from 67 patients with invasive bladder cancer subjected to radical cystectomy, bilateral lymph node dissection, and urinary diversion with or without systemic chemotherapy. Two observers (N.H.C. and T.S.T.), blinded to clinical outcome, reviewed the immunohistochemical staining for p53 (PAb1801) and HER-2/neu (Ab-17). The results were analyzed for progression-free survival and patient survival. Results: Positive staining for p53 and HER-2/neu was found in 30 (44.8%) and 39 (58.2%) patients. In contrast to HER-2/neu, p53 expression was significantly associated with tumor grade and pathologic stage (p = 0.040 and 0.004, respectively), and tended to be related to the nodal status (p = 0.080). Most importantly, coexpression of p53 and HER-2/neu significantly correlated with nodal metastases (p = 0.020). Univariate and multivariate analysis revealed p53 and nodal status as two independent prognostic factors. Additionally, patients with p53 and HER-2/neu coexpression had the shortest time to relapse and overall survival, irrespective of whether adjuvant chemotherapy was given or not (p = 0.005 and 0.030). Conclusions: In invasive bladder cancer, p53 was an important prognostic factor since its expression correlated with tumor grade and stage, even nodal status, whereas HER-2/neu did not show prognostic significance. Tumors with p53 and HER-2/neu coexpression were associated with nodal metastases, probably resulting in decreased progression-free survival. Although some basic studies provide some important supports, studies including larger patient cohorts would still be required to prove the hypothesis that p53 and HER-2/neu-coexpressing tumors have a worse prognosis and are more resistant to a cisplatin-based multidrug regimen.

原文English
頁(從 - 到)262-270
頁數9
期刊Urologia Internationalis
71
發行號3
DOIs
出版狀態Published - 2003 十月 9

指紋

Taiwan
Urinary Bladder Neoplasms
Neoplasms
Disease-Free Survival
Staining and Labeling
Neoplasm Metastasis
Urinary Diversion
Survival
Cystectomy
Adjuvant Chemotherapy
Lymph Node Excision
Paraffin
Cisplatin
Multivariate Analysis
Immunohistochemistry
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Urology

引用此文

@article{0b6bd75902b748ffa8c5e0cb331154a0,
title = "Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan",
abstract = "Objectives: To explore the clinical significance of p53 and HER-2/neu coexpression by immunohistochemistry in patients with invasive bladder cancer in Taiwan. Methods: Paraffin-embedded tumor blocks were obtained from 67 patients with invasive bladder cancer subjected to radical cystectomy, bilateral lymph node dissection, and urinary diversion with or without systemic chemotherapy. Two observers (N.H.C. and T.S.T.), blinded to clinical outcome, reviewed the immunohistochemical staining for p53 (PAb1801) and HER-2/neu (Ab-17). The results were analyzed for progression-free survival and patient survival. Results: Positive staining for p53 and HER-2/neu was found in 30 (44.8{\%}) and 39 (58.2{\%}) patients. In contrast to HER-2/neu, p53 expression was significantly associated with tumor grade and pathologic stage (p = 0.040 and 0.004, respectively), and tended to be related to the nodal status (p = 0.080). Most importantly, coexpression of p53 and HER-2/neu significantly correlated with nodal metastases (p = 0.020). Univariate and multivariate analysis revealed p53 and nodal status as two independent prognostic factors. Additionally, patients with p53 and HER-2/neu coexpression had the shortest time to relapse and overall survival, irrespective of whether adjuvant chemotherapy was given or not (p = 0.005 and 0.030). Conclusions: In invasive bladder cancer, p53 was an important prognostic factor since its expression correlated with tumor grade and stage, even nodal status, whereas HER-2/neu did not show prognostic significance. Tumors with p53 and HER-2/neu coexpression were associated with nodal metastases, probably resulting in decreased progression-free survival. Although some basic studies provide some important supports, studies including larger patient cohorts would still be required to prove the hypothesis that p53 and HER-2/neu-coexpressing tumors have a worse prognosis and are more resistant to a cisplatin-based multidrug regimen.",
author = "Tsai, {Yuh Shyan} and Tzai, {Tzong Shin} and Chow, {Nan Hua} and Yang, {Wen Horng} and Tong, {Yat Ching} and Lin, {Johnny S.N.} and Chang, {Chien Chen} and Cheng, {Hong Lin} and Lin, {Yung Ming}",
year = "2003",
month = "10",
day = "9",
doi = "10.1159/000072676",
language = "English",
volume = "71",
pages = "262--270",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "3",

}

Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. / Tsai, Yuh Shyan; Tzai, Tzong Shin; Chow, Nan Hua; Yang, Wen Horng; Tong, Yat Ching; Lin, Johnny S.N.; Chang, Chien Chen; Cheng, Hong Lin; Lin, Yung Ming.

於: Urologia Internationalis, 卷 71, 編號 3, 09.10.2003, p. 262-270.

研究成果: Article

TY - JOUR

T1 - Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan

AU - Tsai, Yuh Shyan

AU - Tzai, Tzong Shin

AU - Chow, Nan Hua

AU - Yang, Wen Horng

AU - Tong, Yat Ching

AU - Lin, Johnny S.N.

AU - Chang, Chien Chen

AU - Cheng, Hong Lin

AU - Lin, Yung Ming

PY - 2003/10/9

Y1 - 2003/10/9

N2 - Objectives: To explore the clinical significance of p53 and HER-2/neu coexpression by immunohistochemistry in patients with invasive bladder cancer in Taiwan. Methods: Paraffin-embedded tumor blocks were obtained from 67 patients with invasive bladder cancer subjected to radical cystectomy, bilateral lymph node dissection, and urinary diversion with or without systemic chemotherapy. Two observers (N.H.C. and T.S.T.), blinded to clinical outcome, reviewed the immunohistochemical staining for p53 (PAb1801) and HER-2/neu (Ab-17). The results were analyzed for progression-free survival and patient survival. Results: Positive staining for p53 and HER-2/neu was found in 30 (44.8%) and 39 (58.2%) patients. In contrast to HER-2/neu, p53 expression was significantly associated with tumor grade and pathologic stage (p = 0.040 and 0.004, respectively), and tended to be related to the nodal status (p = 0.080). Most importantly, coexpression of p53 and HER-2/neu significantly correlated with nodal metastases (p = 0.020). Univariate and multivariate analysis revealed p53 and nodal status as two independent prognostic factors. Additionally, patients with p53 and HER-2/neu coexpression had the shortest time to relapse and overall survival, irrespective of whether adjuvant chemotherapy was given or not (p = 0.005 and 0.030). Conclusions: In invasive bladder cancer, p53 was an important prognostic factor since its expression correlated with tumor grade and stage, even nodal status, whereas HER-2/neu did not show prognostic significance. Tumors with p53 and HER-2/neu coexpression were associated with nodal metastases, probably resulting in decreased progression-free survival. Although some basic studies provide some important supports, studies including larger patient cohorts would still be required to prove the hypothesis that p53 and HER-2/neu-coexpressing tumors have a worse prognosis and are more resistant to a cisplatin-based multidrug regimen.

AB - Objectives: To explore the clinical significance of p53 and HER-2/neu coexpression by immunohistochemistry in patients with invasive bladder cancer in Taiwan. Methods: Paraffin-embedded tumor blocks were obtained from 67 patients with invasive bladder cancer subjected to radical cystectomy, bilateral lymph node dissection, and urinary diversion with or without systemic chemotherapy. Two observers (N.H.C. and T.S.T.), blinded to clinical outcome, reviewed the immunohistochemical staining for p53 (PAb1801) and HER-2/neu (Ab-17). The results were analyzed for progression-free survival and patient survival. Results: Positive staining for p53 and HER-2/neu was found in 30 (44.8%) and 39 (58.2%) patients. In contrast to HER-2/neu, p53 expression was significantly associated with tumor grade and pathologic stage (p = 0.040 and 0.004, respectively), and tended to be related to the nodal status (p = 0.080). Most importantly, coexpression of p53 and HER-2/neu significantly correlated with nodal metastases (p = 0.020). Univariate and multivariate analysis revealed p53 and nodal status as two independent prognostic factors. Additionally, patients with p53 and HER-2/neu coexpression had the shortest time to relapse and overall survival, irrespective of whether adjuvant chemotherapy was given or not (p = 0.005 and 0.030). Conclusions: In invasive bladder cancer, p53 was an important prognostic factor since its expression correlated with tumor grade and stage, even nodal status, whereas HER-2/neu did not show prognostic significance. Tumors with p53 and HER-2/neu coexpression were associated with nodal metastases, probably resulting in decreased progression-free survival. Although some basic studies provide some important supports, studies including larger patient cohorts would still be required to prove the hypothesis that p53 and HER-2/neu-coexpressing tumors have a worse prognosis and are more resistant to a cisplatin-based multidrug regimen.

UR - http://www.scopus.com/inward/record.url?scp=0141649419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141649419&partnerID=8YFLogxK

U2 - 10.1159/000072676

DO - 10.1159/000072676

M3 - Article

C2 - 14512646

AN - SCOPUS:0141649419

VL - 71

SP - 262

EP - 270

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 3

ER -